|
|
Article: Roche and Hybridon to End R & D Collaboration Targeting HPV and Hepatitis C; Hybridon Plans to Continue Development of Lead Compounds
- Article from:
- PR Newswire
- Article date:
- September 3, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass., Sept. 3 /PRNewswire/ -- Hybridon, Inc., (Nasdaq: HYBN) today announced that it had received notification from F. Hoffmann-La Roche, Ltd. ("Roche") that Roche had decided not to pursue further its antisense collaboration with Hybridon, and was terminating the collaboration effective February 28, 1998. The research and development collaboration began in 1992 and identified lead compounds for both hepatitis C and human papillomavirus (HPV), for which Roche made milestone payments to Hybridon. Roche has indicated that it will assign agreement-related patent rights to the HPV and hepatitis C programs to Hybridon. All licenses granted to Roche under the ...